HEALWELL AI Receives Written Shareholder Approval for Pending Acquisition of Orion Health and Related Financing
Rhea-AI Summary
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) has secured shareholder approval for its previously announced $55 million bought-deal financing and the acquisition of Orion Health Holdings . The approval was obtained through written consent from majority shareholders, eliminating the need for a special meeting.
A Schedule A Bank has granted internal risk approval for a $50 million senior secured credit facility, subject to finalizing a credit agreement. The facility will help fund the cash portion of the Orion acquisition.
The transaction involves issuing approximately 35.7 million Class A Subordinate Voting Shares at $1.61/share, totaling CA$57.4 million. The company expects to issue up to 14.7 million subscription receipts and 31,250 convertible debentures with a 10% annual interest rate. The transaction could result in issuing up to 76.4 million additional Subordinate Voting Shares at prices ranging from $1.61 to $2.50 per share.
Positive
- Secured $55 million bought-deal financing
- Obtained $50 million credit facility approval
- Majority shareholder approval received for acquisition
- No special shareholder meeting required, streamlining the process
Negative
- Significant share dilution with up to 76.4 million new shares to be issued
- Share issuance at $1.61 represents 22.6% discount to market price
- High interest rate of 10% on convertible debentures
- The Company has obtained shareholder approval for its proposed acquisition of Orion Health and its previously announced
$55 million bought-deal financing. - The Company also announced that a Schedule A Bank has obtained internal risk approval for a senior secured credit facility in the amount of
$50 million , subject to the Company finalizing a credit agreement with the Bank. - The Company expects to complete its upsized bought deal offering later this week.
Toronto, Ontario--(Newsfile Corp. - January 14, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce that it has obtained shareholder approval for its previously announced
The Company also announced today that a Schedule A Bank has obtained internal risk approval to make available to the Company, at closing of the Transaction, a senior secured credit facility in the amount of
The Company is continuing to work towards completion of the upsized Offering and now expects closing to take place later this week.
Transaction Details & Shareholder Approval
The details of the Offering and the Acquisition are set out in the Company's news releases dated December 16, 2024 and December 17, 2024.
In connection with the Acquisition, the Company expects to issue approximately 35,652,174 Class A Subordinate Voting Shares ("Subordinate Voting Shares") at an issue price of
In connection with the Offering, if the underwriters' option is fully exercised, the Company expects to issue up to a maximum of (i) 14,662,500 subscription receipts of the Company (the "Subscription Receipts") for units of the Company consisting of one Subordinate Voting Share and one-half of one Subordinate Voting Share Purchase warrant (each whole warrant, a "Warrant") exercisable at a price of
The gross proceeds of the Offering, less
On closing of the Offering, the Company also expects to issue to the underwriters up to a maximum of (i) 607,333 warrants for Subordinate Voting Shares with a three-year term and an exercise price of
The Transaction is subject to the shareholder approval requirements of Sections 607(g) and 611(c) of the TSX Company Manual as: (i) the Transaction involves the issuance of Subordinate Voting Shares at less than
In total across both the Offering and the Acquisition, it is expected that the Transaction may result in the issuance of up to an additional 76,408,625 Subordinate Voting Shares at prices ranging from
In addition to the foregoing securities, a variable number of Subordinate Voting Shares may be issued in satisfaction of the Company's obligations with respect to the Variable Share Consideration at an issue price calculated with reference to the 10-day VWAP for Subordinate Voting Shares shortly before the date of payment. Because the Variable Share Consideration is based on a price to be fixed on a future date, the number of Subordinate Voting Shares issuable in satisfaction of the Variable Consideration may fluctuate. The table below shows an illustrative example of how the anticipated maximum number of Subordinate Voting Shares issuable in connection with the Transaction may vary if the share price used to satisfy the Variable Share Consideration is higher or lower than the Market Price:
| Price per Subordinate Voting Share (for Variable Share Consideration) | |||||
| Total # of Subordinate Voting Shares Issued in Transaction | 117,736,625 | 95,541,959 | 86,343,241 | 83,117,716 | 81,473,331 |
| % Dilution |
The definitive agreements for the Transaction have been and are being negotiated between the Issuer and their respective counterparties at arm's length. The Transaction is not expected to result in the creation of any new control person of the Company, however, one new individual, the vendor in the Acquisition, will become the holder of more than
Shareholders representing a majority of the voting shares of the Company have executed a written consent approving the Transaction, and the TSX has advised the Company that it will be permitted to rely on that written consent as evidence of the required majority shareholder approval in accordance with section 604(d) of the TSX Company Manual, and accordingly that it will not be required to hold a formal special shareholder meeting to seek approval of the Transaction.
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.
About HEALWELL
HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.
About ORION HEALTH
Orion Health is a global healthcare technology company focused on reimagining healthcare for all. Orion Health is leading the change in digital health with health and care organizations to improve the wellbeing of every individual with our world leading Unified Healthcare Platform. Made up of a Virtuoso digital front door, Amadeus digital care record, and Orchestral health intelligence platform - each underpinned by extensive health and social data sets, machine learning, and 30 years of innovation focused purely on improving global well-being. www.orionhealth.com.
Forward Looking Statements
Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements in this press release include statements with respect to, among other things, the closing of the Acquisition and the terms on which it is expected to be completed (including the number of Subordinate Voting Shares that may be issued in respect of the Variable Share Consideration), the anticipated timing to close the upsized Offering, and the ability of the Company to forego a shareholder meeting in respect of the Acquisition. Forward-looking statements are often, but not always, identified by words or phrases such as "expect", "creation", "anticipated", "illustrative", "pending", "subject to", "continuing to" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: the parties' ability to satisfy any remaining conditions precedent to completion of the Acquisition and/or the Offering, including receipt of all outstanding regulatory approvals; HEALWELL's ability to complete the Acquisition and/or the Offering, or to complete them on the terms contemplated; the quantum of the working capital adjustment, deferred purchase price and earn-out amounts that may become due under the Acquisition and whether those amounts will be paid in whole or in part in Subordinate Voting Shares; the Company's ability to successfully negotiate and enter into definitive agreements for a credit facility with a Schedule A bank, and the terms on which that facility may be implemented; the Company's ability to access other sources of debt and equity financing and the terms on which such financing may be provided; the Company's ability to integrate acquired businesses, products and services with its own; the potential for third parties to object to the written shareholder consent obtained by the Company; the stability of general economic and market conditions; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated April 1, 2024, which is available under HEALWELL's SEDAR+ profile at www.sedarplus.com. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237125
FAQ
What is the total value of HEALWELL AI's (HWAIF) financing package for the Orion Health acquisition?
How many new shares will HEALWELL AI (HWAIF) issue for the Orion Health acquisition?
What is the conversion price for HEALWELL AI's (HWAIF) convertible debentures?
When is the expected closing date for HEALWELL AI's (HWAIF) bought deal offering?
